Novartis nabs a new anti-hives use for Xolair in the EU

Novartis ($NVS) won European approval for its injectable Xolair formula as a treatment for chronic hives. As the company points out, it's the only product cleared for patients whose chronic spontaneous urticaria haven't responded to antihistamines. The drug is approved in the U.S. and EU to treat allergic asthma; it brought in $613 million in net sales last year. Release

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.